App-Quantinova.ai

Impact of concurrent medications use on outcome of pancreatic cancer: SEER Medicare analysis.

Muhammad Shaalan Beg - American Society of Clinical Oncology Gastrointestinal (ASCO GI) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

Thiazolidinedione

Analysis of survival outcomes among ethnic minorities with pancreatic cancer treated at an urban academic cancer center.

Erin Jou - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Nab-paclitaxel/gemcitabine first-line therapy in patients with metastatic pancreatic carcinoma and high-bilirubin levels: Data from the German QoliXane Pancreatic Cancer Registry.

Gerrit zur Hausen - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

Gemcitabine

A Population-Based Study of Long-Term Morbidity in Pancreas Cancer Patients.

Katherine Elaine Fero - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

The inhibition of CCR2 to modify the microenvironment in pancreatic cancer mouse model and to support the profiling of the CCR2 inhibitor CCX872-B in patients.

Andrea Wang-Gillam - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

FOLFIRINOX

An open-label phase II trial of G-FLIP (low doses of gemcitabine, 5-FU, leucovorin, irinotecan & oxaliplatin), followed by G-FLIP-DM (G-FLIP + low doses of docetaxel & mitomycin C), used concurrently with ascorbic acid (AA), in patients with advanced pancreatic cancer.

Azriel Hirschfeld - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

Ascorbic acid

Natural progression of symptoms after diagnosis of pancreatic cancer.

Katherine Elaine Fero - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Effect of concurrent chemotherapy on overall survival in elderly bladder cancer patients undergoing radiotherapy: A population-based analysis.

Abhishek Ashok Solanki - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Adjuvant chemotherapy for bladder cancer: A detailed characterization of factors precluding utilization.

Brian Robin Hu - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

A phase I/II study of albumin-bound rapamycin nanoparticles in the treatment of bacillus calmette-guerin refractory non-muscle invasive transitional cell bladder cancer.

James M. McKiernan - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

Rapacan

Venous thromboembolism in metastatic urothelial carcinoma.

Patrik Palacka - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Clinical response to anti-PD1 immunotherapy in a patient with non-seminomatous germ cell tumor and evaluation of the immune landscape in testicular cancer.

Shalin Shah - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

Nivolumab

Mediastinal germ cell tumors and development of secondary leukemia and solid tumors.

Nicholas A Madden - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Association of preoperative testosterone levels with testicular germ cell tumor histology.

Siamak Daneshmand - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Cardiovascular risk and the impact of self-reported physical activity in long-term testicular cancer survivors: A longitudinal study.

Hege Sagstuen Haugnes - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Intratumoral heterogeneity and chemo-resistance in nonseminomatous germ cell tumor of the testis.

Mehmet Asim Bilen - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Large retroperitoneal lymphadenopathy (RPLN) and increased risk of venous thromboembolism (VTE) in patients (pts) with metastatic germ cell tumours (mGCT): A Global Germ Cell Cancer Group (G3) Study.

Ben Tran - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Impact of urologist density and county rurality on the practice of retroperitoneal lymph node dissection and cancer specific death in patients with non seminomatous germ cell tumors.

Shaheen Riadh Alanee - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

The impact of insurance status on performance of retroperitoneal lymph node dissection and cancer specific death in patients with non seminomatous germ cell tumors.

Shaheen Riadh Alanee - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Array-comparative genomic hybridization to predict resistance to VEGF-targeted therapies in patients with metastatic clear cell renal cell carcinoma.

Solene-Florence Kammerer-Jacquet - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Filters

41730 Abstracts